U.S., Dec. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07276386) titled 'Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma' on Dec. 01.
Brief Summary: This Phase 2 study evaluates the efficacy and safety of sequential treatment with percutaneous hepatic perfusion (PHP) using melphalan/HDS followed by tebentafusp in patients with metastatic uveal melanoma (mUM) with isolated liver metastases. The rationale is that PHP enhances antigen release and immunomodulation, potentially sensitizing tumors to tebentafusp in HLA-A*02:01-positive patients.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Metastatic Uveal Melanoma
Intervention:
DRUG:...